COVID-19 in patients with juvenile idiopathic arthritis: frequency and severity
More details
Hide details
Department of Children’s Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
Regional Children’s Hospital, Ternopil, Ukraine
Online publication date: 2021-09-08
Reumatologia 2021;(Konferencja Pacjent post-COVID-owy. Co zostaje, a co się zmienia? 1):197-199
The aim of the study was to determine the frequency and the course of COVID-19 infection in children with juvenile idiopathic arthritis (JIA). The study involved 51 patients with JIA aged 2 to 18 years. Evidence of COVID-19 was found in 10 (19.6%) patients with JIA. COVID-19 infection occurred more often in patients with systemic arthritis (OR = 6.1667, 95% CI: 1.2053–31.5511, p = 0.0289). The course of COVID-19 infection in patients with JIA was generally similar to the course in the pediatric population, despite immunosuppressive therapy. In 3 out of 10 patients the infection caused an exacerbation of JIA, which required therapy escalation.
Patel NA. Pediatric COVID-19: systematic review of the literature. Am J Otolaryngol 2020; 41: 102573, DOI: 10.1016/j.amjoto.2020.102573.
Toptan T, Ciesek S, Hoehl S. Pediatrics and COVID-19. Adv Exp Med Biol 2021; 1318: 197–208, DOI: 10.1007/978-3-030-63761-3_12.
Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73: e13–e29, DOI: 10.1002/art. 41616.
Sancho-Shimizu V, Brodin P, Cobat A, et al. SARS-CoV-2-related MIS-C: a key to the viral and genetic causes of Kawasaki disease? J Exp Med 2021; 218: e20210446, DOI: 10.1084/jem. 20210446.
Makowska J, Styrzyński F. Between COVID-19 severity and its prevention – what should rheumatologists be aware of? Reumatologia 2021; 59: 1–2, DOI: 10.5114/reum.2021.103941.
Leszczyński P. COVID-19: a short message to rheumatologists. Reumatologia 2020; 58: 130–133, DOI: 10.5114/reum. 2020.96685.
Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2020; 2: e557–e564, DOI: 10.1016/S2665-9913(20)30227-7.
FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020; 80: 527–538, DOI: 10.1136/annrheumdis-2020-218310 [Online ahead of print].
Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021; 7: e001464, DOI: 10.1136/rmdopen-2020-001464.
Licciardi F, Giani T, Baldini L, et al. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol Online J 2020; 18: 35, DOI: 10.1186/s12969-020-00422-z.
Yildiz M, Haslak F, Adrovic A, et al. The frequency and clinical course of COVID-19 infection in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2020; 38: 1271–1272.
Calvo C, Udaondo C; Rheumatic Diseases EPICO-AEP Working Group. COVID-19 in children with rheumatic diseases in the Spanish National Cohort EPICO-AEP. J Rheumatol 2021, DOI: 10.3899/jrheum.201548 [Online ahead of print].
Boyarchuk O, Kovalchuk T, Kovalchuk N, Chubata O. Clinical variability of the systemic juvenile idiopathic arthritis course: literature review based on case series. Reumatologia 2020; 58: 436–443, DOI: 10.5114/reum.2020.10201.
Filocamo G, Minoia F, Carbogno S, et al. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol 2020, DOI: 10.3899/jrheum.200483 [Online ahead of print].
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top